8-K: Tenaya Therapeutics Announces Positive Interim Data and Extends Cash Runway into Second Half of 2026

Tenaya Therapeutics reports encouraging interim data from its TN-201 clinical trial, highlights unmet needs in ARVC, and extends its cash runway into the second half of 2026.

Summary

• Tenaya Therapeutics announced its first quarter 2025 financial results and provided a business update.
• Interim data from the MyPEAK-1 clinical trial of TN-201 showed an encouraging safety profile, transduction, and expression, along with improvements in hypertrophy and NYHA classification.
• The RIDGE natural history and seroprevalence study highlighted a significant disease burden and unmet need among adults with PKP2-associated ARVC.
• Data readouts for the TN-201 and TN-401 clinical programs are on track for the second half of 2025.
• The company's cash runway has been extended into the second half of 2026.
• In March 2025, Tenaya shared new interim data from the first cohort enrolled in the MyPEAK-1 Phase 1b/2 clinical trial of TN-201 at the 2025 American College of Cardiology Scientific Sessions.
• All three patients in the first cohort of the MyPEAK-1 trial achieved New York Heart Association (NYHA) Class I post-treatment.
• Enrollment in Cohort 2 of the MyPEAK-1 trial was initiated in December 2024 at the 6E13 vg/kg dose.
• Tenaya expects to share initial Cohort 2 data along with further follow-up data from Cohort 1 in the second half of 2025.
• Enrollment of the first cohort of patients receiving TN-401 in the RIDGE-1 Phase 1b clinical trial is on track for completion in the first half of 2025.
• Tenaya expects to share initial Cohort 1 data from the RIDGE-1 trial in the second half of 2025.
• In February 2025, Tenaya was awarded an $8.0 million clinical grant from the California Institute for Regenerative Medicine (CIRM) to help fund clinical trial costs for the RIDGE-1 trial of TN-401.
• In March 2025, Tenaya completed an underwritten public offering with net proceeds of approximately $48.8 million.
• Tenaya implemented a restructuring plan, including cost containment measures and a workforce reduction, to extend its cash runway.
• Tenaya estimates that it will incur approximately $1.6 million to $2.7 million of aggregate charges related to the restructuring plan.
• As of March 31, 2025, cash, cash equivalents, and investments in marketable securities were $88.2 million.
• R&D expenses were $21.1 million for the first quarter of 2025, compared to $25.1 million for the same period in 2024.
• G&A expenses were $6.5 million for the first quarter of 2025, compared to $8.7 million for the same period in 2024.
• Net loss was $26.9 million, or $0.24 loss per share, for the first quarter ended March 31, 2025, compared to a net loss of $32.2 million, or $0.40 per share, in the same period of 2024.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. Positive clinical data and extended cash runway are encouraging, but the restructuring plan and workforce reduction indicate cost-cutting measures. The sentiment is cautiously optimistic.

Positives

• Interim data from the MyPEAK-1 clinical trial of TN-201 showed an encouraging safety profile, transduction, and expression.
• All three patients in the first cohort of the MyPEAK-1 trial achieved New York Heart Association (NYHA) Class I post-treatment.
• Tenaya's cash runway has been extended into the second half of 2026.
• Tenaya completed an underwritten public offering in March 2025, raising approximately $48.8 million in net proceeds.
• Tenaya received an $8.0 million grant from CIRM to support the RIDGE-1 clinical trial of TN-401.
• R&D and G&A expenses decreased compared to the same period in 2024.
• Net loss per share improved from $0.40 to $0.24 compared to the same period in 2024.

Negatives

• Tenaya implemented a restructuring plan, including a workforce reduction, to extend its cash runway.
• Tenaya estimates that it will incur approximately $1.6 million to $2.7 million of aggregate charges related to the restructuring plan.
• The company reported a net loss of $26.9 million for the first quarter of 2025.

Risks

• The forward-looking statements are subject to risks and uncertainties, including the potential failure of Tenaya's product candidates to demonstrate safety and/or efficacy in clinical testing.
• There is a risk that clinical trial results may differ from preclinical, interim, preliminary, topline, or expected results.
• Tenaya's ability to raise additional funding is subject to risks.
• The company's reliance on third parties poses a risk.
• Competition in the industry in which Tenaya operates is a risk.
• The impact of the restructuring plan on Tenaya's business is a risk.

Future Outlook

Tenaya expects to share data from its MyClimb study and initial data from Cohort 2 of the MyPEAK-1 trial and Cohort 1 of the RIDGE-1 trial in the second half of 2025. The company expects its current funds to support planned operations into the second half of 2026.

Management Comments

• '2025 is off to a strong start for Tenaya as we delivered positive data from our MyPEAK-1 clinical trial evaluating TN-201 for the potential treatment of MYBPC3-associated HCM, shared new findings from the RIDGE natural history study of adults with PKP2-associated ARVC, and extended our cash runway into the second half of 2026,' said Faraz Ali, Chief Executive Officer of Tenaya.
• Faraz Ali also stated that patient enrollment is on track for both the MyPEAK-1 study for TN-201 and the RIDGE-1 study for TN-401 as they drive both programs toward meaningful clinical readouts in the second half of this year.
• Management has taken important steps to focus financial resources on clinical execution to help ensure they can take TN-201 and TN-401 through to important clinical milestones in 2026.

Industry Context

Tenaya's focus on gene therapies for heart disease aligns with the growing interest in genetic medicines for treating underlying causes of disease. The company's programs targeting specific genetic mutations in HCM and ARVC position it within a competitive landscape of companies developing precision therapies for cardiovascular disorders.

Comparison to Industry Standards

• The data from the first three patients showed that TN-201 was well tolerated at a dose of 3E13 vg/kg.
• Biopsy results from all three patients demonstrated robust DNA transduction and RNA expression similar to or greater than ranges observed in other AAV cardiac gene therapy trials.
• The RIDGE study is the largest natural history study conducted to date in this population and has enrolled more than 175 adult participants with PKP2-associated ARVC at more than 20 clinical sites in the U.S., UK, and EU.

Stakeholder Impact

• Shareholders: The positive clinical data and extended cash runway are positive for shareholders, but the restructuring plan and workforce reduction may raise concerns.
• Employees: The workforce reduction will negatively impact affected employees.
• Patients: The potential for new therapies for heart disease is positive for patients.

Next Steps

• Complete enrollment of Cohort 2 in the MyPEAK-1 trial in the first half of 2025.
• Share initial Cohort 2 data along with further follow-up data from Cohort 1 in the second half of 2025.
• Share data from the MyClimb study in the second half of 2025.
• Complete enrollment of the first cohort of patients receiving TN-401 in the RIDGE-1 Phase 1b clinical trial in the first half of 2025.
• Share initial Cohort 1 data from the RIDGE-1 trial in the second half of 2025.

Key Dates

Keywords

Tenaya Therapeutics, TN-201, TN-401, MYBPC3-associated HCM, PKP2-associated ARVC, Gene Therapy, Clinical Trial, Financial Results, Cash Runway, RIDGE Study, MyPEAK-1, Biotechnology